54
T.C. Peterson et al. / European Journal of Pharmacology 662 (2011) 47–54
Feagan, B.G., 2003. Maintenance therapy for inflammatory bowel disease. Am. J.
Gastroenterol. 98, S6–S17.
Fiocci, C., 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenter-
ology 115, 182–205.
Fix, C., Bingham, K., Carver, W., 2011. Effects of interleukin-18 on cardiac fibroblast
function and gene expression. Cytokine 53, 19–28.
Haas, S.L., Abbatista, M., Brade, J., Singer, M.V., Bocker, U., 2009. Interleulin-18 serum
levels in inflammatory bowel disease; correlation with disease activity and
inflammatory markers. Swiss Med Wkly 139, 140–145.
Haber, P.S., Keough, G.W., Apte, M.V., Moran, C.S., Stewart, N.L., Crawford, D.H., Pirola, R.C.,
McCaughan, G.W., Ramm, G.A., Wilson, J.S., 1999. Activation of pancreatic stellate
cells in human and experimental pancreatic fibrosis. Am. J. Pathol. 155,
1087–1095.
Peterson, T.C., 1993. Pentoxifylline prevents fibrosis in an animal model and inhibits
platelet-derived growth factor-driven proliferation of fibroblasts. Hepatology 17,
486–493.
Peterson, T.C., Davey, K., 1997. Effect of acute pentoxifylline treatment in an
experimental model of colitis. Aliment. Pharmacol. Ther. 11, 575–580.
Peterson, T.C., Isbrucker, R., Hooper, M.L., 1994. In vitro effect of platelet-derived
growth factor on fibroproliferation and effect of cytokine antagonists. Immuno-
pharmacol 28, 259–270.
Peterson, T.C., Peterson, M.R., Wornell, P.A., Blanchard, M.G., Gonzalez, F.J., 2004. Role of
CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction. Biochem.
Pharmacol. 68, 395–402.
Pinzani, M., 1995. Novel insights into the biology and physiology of the Ito cell.
Pharmacol. Ther. 66, 387–412.
Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F.,
Rachmilewitz, D., Wolf, D.C., Olson, A., Bao, W., Rutgeerts, P., ACCENT I Study Group,
2002. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial.
Lancet 359, 1541–1549.
Harper, P.H., Fazio, V.W., Lavery, I.C., Jagelman, D.G., Weakley, F.L., Farmer, R.G., Easley,
K.A., 1987. The long-term outcome in Crohn's disease. Dis. Colon Rectum 30,
174–179.
Isbrucker, R.A., Peterson, T.C., 1998. Platelet-derived growth factor and pentoxifylline
modulation of collagen synthesis in myofibroblasts. Toxicol. Appl. Pharmacol. 149,
120–126.
Preaux, A.M., Mallat, A., Rosenbaum, J., Zafrani, E.S., Mauvier, P., 1997. Pentoxifylline
inhibits growth and collagen synthesis of cultured human myofibroblasts-like cells.
Hepatology 26, 315–322.
Pucilowska, J.B., Williams, K.L., Lund, P.K., 2000. Fibrogenesis IV. Fibrosis and
inflammatory bowel disease: cellular mediators and animal models. Am. J. Physiol.
Gastrointest. Liver Physiol. 279, G653–G659.
Puig-Divi, V., Molero, X., Salas, A., Guarner, F., Guarner, L., Malagelada, J.R., 1996.
Induction of chronic pancreatic disease by trinitrobenzene sulfonic acid infusion
into rat pancreatic ducts. Pancreas 13, 417–424.
Raoul, J.M., Peterson, M.R., Peterson, T.C., 2007. A novel drug interaction between the
Isik, F., Tunali, Akbay.T., Yarat, A., Genc, Z., Pisiriciler, R., Caliskan-Ak, E., Cetinel, S.,
Altıntas, A., Sener, G., 2011. Protective effects of black cumin (Nigella sativa) oil on
TNBS-induced experimental colitis in rats. Dig. Dis. Sci. 56, 721–730.
Jimenez, J.L., Punzon, C., Navarro, J., Muñoz-Fernández, M.A., Fresno, M., 2001.
Phosphodiesterase 4 inhibitors prevent cytokine secretion by T-lymphocytes by
inhibiting nuclear factor-κB and nuclear factor of activated T cells activation.
J. Pharmacol. Exp. Ther. 229, 753–759.
quinolone antibiotic ciprofloxacin and
Biochem. Pharmacol. 74, 639–646.
a chiral metabolite of pentoxifylline.
Reimund, J.M., Dumont, S., Muller, C.D., Kenney, J.S., Kedinger, M., Baumann, R.,
Poindron, P., Duclos, B., 1997. In vitro effects of oxpentifylline on inflammatory
cytokine release in patients with inflammatory bowel disease. Gut 40, 475–480.
Rogler, G., Andus, T., 1998. Cytokines in inflammatory bowel disease. World J. Surg. 22,
382–389.
Khan, F., Peltekian, K.M., Peterson, T.C., 2008. Effect of interferon-alpha, ribavirin,
pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic
stellate cell proliferation. J. Interferon Cytokine Res. 28, 643–651.
Kimura, R., Hu, H., Stein-Steillien, J., 1992. Delayed-type hypersensitivity responses
regulate collagen deposition in the lung. Immunology 77, 550–555.
Krawisz, J.E., Sharon, W.F., 1984. Quantitative assay for acute intestinal inflammation
based on myeloperoxidase activity. Gastroenterology 87, 1344–1350.
Last, J.A., Ward, R., Temple, L., Pinkerton, K.E., Kenyon, N.J., 2004. Olvalbumin-induced
airway inflammation and fibrosis in mice also exposed to ultrafine particles. Inhal.
Toxicol. 16, 93–102.
Lawrance, I.C., Maxwell, L., Doe, W., 2001. Altered response of intestinal mucosal
fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm.
Bowel Dis. 7, 226–236.
Lin, S.L., Chen, Y.M., Chien, C.T., Chiang, W.C., Tsai, C.C., Tsai, T.J., 2002. Pentoxifylline
attenuated the renal disease progression in rats with remnant kidney. J. Am. Soc.
Nephrol. 13, 2916–2929.
Stein, R.B., Hanauer, S.B., 2000. Comparative tolerability of treatments for inflammatory
bowel disease. Drug Saf. 23, 429–448.
Rojas-Cartagena, C., Flores, I., Appleyard, C.B., 2005. Role of tumor necrosis factor
receptors in an animal model of acute colitis. Cytokine 32, 85–93.
Samardzic, T., Jankovic, V., Stosic-Grujicic, S., Popadic, D., Trajkovic, V., 2001.
Pentoxifylline inhibits the synthesis and IFN-gamma-inducing activity of IL-18.
Clin. Exp. Immunol. 124, 274–281.
Sturm, A., Zeeh, J., Sudermann, T., Rath, H., Gerken, G., Dignass, A., 2002. Lisofylline and
lysophospholipids ameliorate experimental colitis in rats. Digestion 66, 23–29.
Valente, E.G.A., Vernet, D., Ferrini, M.G., Qian, A., Rajfer, J., Gonzalez-Cadavid, N.F., 2003.
L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the
Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 9, 229–244.
Verma, M., Peterson, M.R., Peterson, T.C., 2007. Effect of fetuin, a TGF beta antagonist
and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and
fibrotic parameters in fibrosis. Eur. J. Pharmacol. 572, 220–227.
Videla, S., Garcia-Lafuente, A., Antolin, M., Vilaseca, J., Guarner, F., Crespo, E., Gonzalez,
G., Salas, A., Malagelada, J.R., 1998. Antitumor necrosis factor therapy in rat chronic
granulomatous colitis: critical dose-timing effects on outcome. J. Pharmacol. Exp.
Ther. 287, 854–859.
Lopez de Leon, A., Rojkind, M., 1985. A simple micromethod of for collagen and total
protein determination in formalin-fixed paraffin-embedded sections. J. Histochem.
Cytochem. 33, 737–743.
Miroliaee, A.E., Esmaily, H., Vaziri-Bami, A., Baeeri, M., Shahverdi, A.R., Abdollahi, M.,
2011. Amelioration of experimental colitis by a novel nanoselenium–silymarin
mixture. Toxicol. Mech. Methods 21, 200–208.
Vukanić, Z.S., Colić, M., Dimitrijević, M., 2007. Effect of pentoxifylline on differentiation
and maturation of human monocyte-derived dendritic cells in vitro. Int.
Immunopharmacol. 7, 167–174.
Morris, G.P., Beck, P.L., Herridge, M.S., Depew, W.T., Szewezuk, M.R., Wallace, J.L., 1989.
Hapten-induced model of chronic inflammation and ulceration in the rat colon.
Gastroenterology 96, 795–803.
Mourelle, M., Salas, A., Vilaseca, J., Guarner, F., Malagelada, J.R., 1995. Induction of
chronic cholangitis in the rat by trinitrobenzenesulfonic acid. J. Hepatol. 22,
219–225.
Murphy, G.J., Nicholson, M.L., 2003. Rapamycin has no effect on fibrosis-associated gene
expression or extracellular matrix accumulation when administered to animals
with established or early allograft vasculopathy. J. Thorac. Cardiovasc. Surg. 126,
2058–2064.
Murthy, S., Cooper, H.S., Yoshitake, H., Meyer, C., Meyer, C.J., Murthy, N.S., 1999.
Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in
dextran sulphate sodium-induced mouse colitis. Aliment. Pharmacol. Ther. 13,
251–260.
Wallace, J.L., 1987. Glucocorticoid-induced gastric mucosal damage: inhibition of
leukotriene, but not prostaglandin biosyntheisis. Prostaglandins 34, 311–323.
Wallace, J.L., MacNaughton, W.K., Morris, G.P., Beck, P.L., 1989. Inhibition of leukotriene
synthesis markedly accelerates healing in a rat model of inflammatory bowel
disease. Gastroenterology 96, 29–36.
Ward, A., Clissold, S.P., 1987. Pentoxifylline, a review of its pharmacodynamic and
pharmacokinetic properties and therapeutic efficacy. Drugs 34, 50–97.
Yin, B., Hu, X., Wang, J., Liang, H., Li, X., Niu, N., Li, B., Jiang, X., Li, Z., 2011. Blocking TNF-α
by combination of TNF-α- and TNFR-binding cyclic peptide ameliorates the
severity of TNBS-induced colitis in rats. Eur. J. Pharmacol. 656 (1–3), 119–124.
Zar, J.H., 1974. Biostatistical Methods. Prentice-Hall, Englewood Cliffs, N.J.
Zhang-Hoover, J., Sutton, A., van Rooijen, N., Stein-Streilein, J., 2000. A critical role for
alveolar macrophages in elicitation of pulmonary immune fibrosis. Immunology
101, 501–511.